RESEARCH ARTICLES

319 Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial
Emma H. Allott, Lauren E. Howard, Adriana C. Vidal, Daniel M. Moreira, Ramiro Castro-Santamaría, Gerald L. Andriole, and Stephen J. Freedland

327 Sleep Duration across the Adult Lifecourse and Risk of Lung Cancer Mortality: A Cohort Study in Xuanwei, China

337 Bitter Melon Enhances Natural Killer–Mediated Toxicity against Head and Neck Cancer Cells
Sourav Bhattacharya, Naoshad Muhammad, Robert Steele, Jacki Kornbluth, and Ratna B. Ray

345 Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention

CORRECTION

355 Combined Genetic Biomarkers and Betel Quid Chewing for Identifying High-Risk Group for Oral Cancer Occurrence
Chia-Min Chung, Chien-Hung Lee, Mu-Kuan Chen, Ka-Wo Lee, Cheng-Che E. Lan, Aij-Lie Kwan, Ming-Hsue Tsai, and Ying-Chin Ko

363 A Presurgical Study of Lecithin Formulation of Green Tea Extract in Women with Early Breast Cancer
Matteo Lazzeroni, Aliana Guerrieri-Gonzaga, Sara Gandini, Harriet Johansson, Davide Serrano, Massimiliano Cazzaniga, Valentina Arisarco, Debora Macis, Serena Moro, Pietro Caldarella, Gianmatteo Pagani, Giancarlo Pruneri, Antonella Riva, Giovanna Petrangolini, Paolo Morazzoni, Andrea DeCensi, and Bernardo Bonanni

371 Correction: New Perspectives of Curcumin in Cancer Prevention

ABOUT THE COVER

There are approximately 150,000 new cases of colorectal cancer (CRC) in the United States annually. Even with improvements in screening, early detection, and treatment, CRC remains the second leading cause of cancer-related mortality in this country. Chemoprevention for many common human cancers remains an elusive goal despite substantial research efforts. Non-steroidal anti-inflammatory agents, including aspirin, do offer some protection against colorectal neoplasia, however, the risk/benefit ratio associated with these drugs argues against their regular use for chemoprevention alone. Therefore, identification of new CRC chemopreventive agents is needed. In this issue, the proposed anti-neoplastic mechanism of action for linaclotide is explored (see article by Weinberg et al.; beginning on page 345). Compared to placebo, oral linaclotide administered to healthy humans reduces colorectal crypt proliferation quantified by Ki67 immunohistochemistry (as represented in an adaptation of Figure 4). This effect was seen in endoscopically obtained colonic mucosal specimens from cecum to rectum. As linaclotide has been approved by the FDA to treat constipation, with an excellent safety record to date, this article considers future steps required to develop an optimized formulation for CRC chemoprevention.